Ascletis Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASCLF research report →
Price Chart
About the company
Ascletis Pharma Inc. , a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.
- CEO
- Jinzi J. Wu
- IPO
- 2019
- Employees
- 202
- HQ
- Hangzhou, ENG, CN
Get TickerSpark's AI analysis on ASCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.14B
- P/E
- -10.92
- PEG
- 0.14
- P/S
- 7132.61
- P/B
- 2.95
- EV/EBITDA
- -9.48
- Div Yield
- 0.00%
- Gross Margin
- -863.41%
- Op Margin
- -70395.30%
- Net Margin
- -62508.34%
- ROE
- -28.15%
- ROIC
- -29.29%
Latest fiscal year · YoY change
- Revenue
- $1.98M+54.0%
- Gross Profit
- $-16,648,975-2365.2%
- Op Income
- $-471,274,213
- Net Income
- $-350,592,985-16.5%
- EPS
- $-0.36-20.0%
- OCF Growth
- +3.6%
- FCF Growth
- +3.7%
- 52W High
- $2.50
- 52W Low
- $1.04
- 50D MA
- $1.21
- 200D MA
- $1.63
- Beta
- 0.43
- RSI (14)
- 40
- Avg Volume
- 736
No earnings-call transcripts are available for ASCLF yet.
- Free Float
- 19.6%
- Shares Outstanding
- 1.05B
- Float Shares
- 205.23M
Our ASCLF coverage
Recent articles, reports, and earnings notes.
No research on ASCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASCLF report →Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
prnewswire.com · Jun 23
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
prnewswire.com · Jun 7
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
prnewswire.com · May 5
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
prnewswire.com · Apr 29
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
prnewswire.com · Apr 26
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
prnewswire.com · Apr 7
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
prnewswire.com · Mar 10
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
prnewswire.com · Feb 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.